Эпизоды
-
Elizabeth Pemmerl, Chief Revenue Officer at GitHub, speaks with Venrock partner Ethan Batraski to discuss her nearly decade-long journey with GitHub. Pemmerl shares how she transitioned from working in the public sector to GitHub, go-to-market strategies, balancing developer vs. enterprise needs, changing developer behavior and more.
-
David Stark, Chief Medical Officer at Morgan Stanley, speaks with Venrock partner Bob Kocher to discuss his career journey from practicing medicine to taking a non-clinical role in business. Stark shares how he views his role as Chief Medical Officer, advice for other doctors who want to transition out of practicing medicine, what he’s proudest of at Morgan Stanley and more.
-
Пропущенные эпизоды?
-
Alex Rosemblat, former Chief Marketing Officer at Datadog, speaks with Venrock partner Ethan Batraski to discuss his 11-year run at the helm of Datadog’s Marketing Team and what’s next for his career. Rosemblat shares insights into leading Datadog’s go-to-market strategy, advice for other marketing leaders tackling this for a new product or company for the first time, his biggest learning from Datadog and more. During the conversation, Rosemblat recommended Digital CMO's Guide to Marketing Measurement by Bryan Semple.
Book mentioned: https://vnrk.co/3VuFvxg -
Heather Turner, CEO at Carmot Therapeutics, speaks with Venrock partner Nimish Shah to discuss her time as CEO. Turner shares how she guided the company through its acquisition by Roche, advice for other CEOs on the verge of an acquisition, her perspective on the GLP-1 market and what excites her about the future of biotech.
-
Mark McKenna, chairman and CEO at Mirador Therapeutics, speaks with Venrock partner Nimish Shah to discuss his most recent role at Prometheus Biosciences and the beginning of his new company, Mirador. McKenna shares a behind-the-scenes look into leading Prometheus during its acquisition by Merck, why he started Mirador Therapeutics, advice for other CEOs, what he values in a team and more.
-
We have a special episode today because Venrock’s 8th annual Healthcare Prognosis results are in! From drugs (e.g., GLP-1s, pricing negotiations) to fundraising and optimism around the equity market to cybersecurity and AI regulations - this year’s survey covers it all. In this episode, partners Bryan Roberts and Bob Kocher sit down to share their perspectives on the most interesting findings.
-
Sami Inkinen, founder and CEO of Virta Health, speaks with Venrock partner Bob Kocher to discuss how Virta has evolved since he was on the podcast seven years ago. Inkinen shares how he views the GLP-1 craze, insights on his go-to-market strategy, advice for founders entering the healthcare market, and how Virta uses AI and technology.
-
Latané Conant, Chief Revenue Officer at 6sense, speaks with Venrock partner Brian Ascher to discuss how her previous marketing role prepared her for her promotion to Chief Revenue Officer. Conant shares her approach to keeping product market fit, her opinion on Marketing Qualified Leads (MQLs), how AI could impact sales and marketing and more.
-
Isan Chen, CEO of MBrace Therapeutics, speaks with Venrock partner Racquel Bracken to discuss his career trajectory leading up to his founding of MBrace. Chen shares the impetus behind his decision to become an oncologist, why he switched from academic medicine to the industry side, lessons learned from years in drug development and more.
-
Patrick Conway, CEO of Optum Rx, sits down with Venrock partners Bryan Roberts and Bob Kocher to discuss his first few months on the job. Conway also shares his views on the best early metric indicators of success, the effectiveness of Medicare Advantage Star Ratings, the role of technology in value-based care and more.
-
Ed Park, co-founder and CEO of Devoted Health, sits down with Venrock partners Bryan Roberts and Bob Kocher to discuss the founding of Devoted. Park talks about his priorities for the next five years, the value he sees in AI and LLMs, Medicare Advantage industry changes, his favorite interview question for job candidates and more.
-
Ying Huang, CEO of Legend Biotech, speaks with Venrock partner Nimish Shah about his career path to Legend Biotech and the lessons he learned from transitioning from Wall Street to an operating role. Huang also discusses what he prioritized when he first started the role, the most rewarding parts of his job and what characteristics he looks for when hiring people for his team.
-
Brad Stulberg, best-selling author of The Practice of Groundedness and co-author of Peak Performance, speaks with Venrock partner Bob Kocher about Stulberg’s new book, Master of Change: How to Excel When Everything is Changing—Including You. Stulberg and Kocher discuss ways to rethink change, the concept of rugged flexibility and paths for embracing and growing from life’s constant instability.
-
Senthil Sundaram, CEO of Terns Pharmaceuticals, speaks with Venrock’s Nimish Shah about the lessons learned balancing personal health events while being CEO of a young company. Sundaram also discusses the "Working Genius" model, an approach focused on leveraging the types of work that bring an employee energy, and his attitude towards team-based leadership and how it propels growth in the workplace.
-
Dr. Sheila Gujrathi, a biotech industry veteran with a strong track record as an entrepreneur, physician executive, translational scientist, board member, and drug developer, speaks with Venrock’s Nimish Shah about the lessons learned in her career at biotech companies both big (Genentech) and small (Gossamer Bio, Receptos, Inc.). Dr. Gujrathi also discusses the importance of building a team of people with shared values, the most challenging parts of being a CEO, and how she’s helping to push diversity in biotech forward.
-
Sam Kintz, co-founder, and CEO of Enliven Therapeutics, speaks with Venrock partner Nimish Shah about the journey that led him to found Enliven. Kintz delves into lessons learned during his time at Roche Venture Fund, and how his time at Stemcentrx and Abbvie revealed what truly matters most to him – being a part of an entire drug development story. Kintz discusses his decision to pursue a reverse merger (and how he persuaded everyone involved to follow this path), what defines a great leader, and shares the best advice he received from one of his mentors.
-
Venrock partners Andrew Gottesdiener and Nimish Shah speak with Michael Henderson, CEO of Apogee Therapeutics, about his role’s unique challenges and opportunities. Henderson discusses his accelerated career trajectory, valuable lessons that have helped shape his success, and Apogee’s recent Series B financing round. Henderson delves into the importance of culture building, including Apogee’s guiding principles (CORE: Care, Original, Resilient, Ego-Less), and his strategies for navigating a challenging biotech industry.
-
Venrock’s Nick Beim speaks with Steve Lockshin, founder of Vanilla, about lessons learned as a serial entrepreneur in wealth management services. Lockshin shares what drives him as an entrepreneur, the need for more digestible information in estate planning, and his most valuable lessons learned on the path to building Vanilla. Lockshin also discusses the importance of humility and how it helped guide his decisions as a business leader.
-
Venrock partner Nick Beim speaks with Bill McNabb, former chairman and CEO of Vanguard, an asset management company that pioneered low-cost investing for the consumer. McNabb shares important leadership lessons including the importance of being humble, having a clear definition of success, and knowing what makes a high-performing team. McNabb reveals significant decisions he made during his time at Vanguard, such as having “no layoffs” during a crisis, and highlights the importance of thinking long-term while still being agile.
-
Farzad Mostashari, founder and CEO of Aledade, speaks with Venrock’s Bryan Roberts and Bob Kocher about improving the quality and efficiency of patient care with a focus on preventative care. With the recent launch of Aledade Care Solutions and new focus on Medicare Advantage, Mostashari delves into Aledade’s efforts to scale and deliver where average primary care practices can’t. Mostashari also reveals his approach to value based care incentive structure, and why building a valuable solution requires a long time horizon.
- Показать больше
